Janux Therapeutics (JANX) Other Gross PP&E Adjustments (2020 - 2025)
Janux Therapeutics (JANX) has disclosed Other Gross PP&E Adjustments for 6 consecutive years, with -$13.4 million as the latest value for Q4 2025.
- On a quarterly basis, Other Gross PP&E Adjustments fell 1.98% to -$13.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.4 million, a 1.98% decrease, with the full-year FY2025 number at -$13.4 million, down 1.98% from a year prior.
- Other Gross PP&E Adjustments was -$13.4 million for Q4 2025 at Janux Therapeutics, down from -$8.1 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $2.7 million in Q1 2022 to a low of -$18.9 million in Q2 2022.
- A 5-year average of -$9.6 million and a median of -$10.5 million in 2024 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: crashed 20892.94% in 2022, then surged 34.95% in 2023.
- Janux Therapeutics' Other Gross PP&E Adjustments stood at $85000.0 in 2021, then plummeted by 20892.94% to -$17.7 million in 2022, then grew by 15.55% to -$14.9 million in 2023, then increased by 11.68% to -$13.2 million in 2024, then fell by 1.98% to -$13.4 million in 2025.
- Per Business Quant, the three most recent readings for JANX's Other Gross PP&E Adjustments are -$13.4 million (Q4 2025), -$8.1 million (Q3 2025), and -$7.8 million (Q2 2025).